产品
编 号：F193962
分子式：C21H26N2O3
分子量：354.44
分子式：C21H26N2O3
分子量：354.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
240
In-stock
500mg
400
In-stock
结构图
CAS No: 1617-90-9
产品详情
生物活性：
Vincamine?is a monoterpenoid indole alkaloid extracted from the?Madagascar periwinkle. Vincamine?is a peripheral?vasodilator?and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine?is a?GPR40?agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS).?Vincamine?improves glucose homeostasis?in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.
体内研究：
Vincamine (intraperitoneal injection; 15 and 30?mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion?in vivo.Animal Model:Male and female db/db mice (BKS.Cg-Dock7m+/+Leprdb/J) and HFD/STZ-induced type 2 diabetic model mice
Dosage:15 and 30?mg/kg/day
Administration:Intraperitoneal injection; 15 and 30?mg/kg/day; 6 weeks
Result:Enhanced glucose tolerance in HFD/STZ and?db/db male mice.
体外研究：
Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi?cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells.Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, ?after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner.Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer.Vincamine could activate GPR40 (EC50=6.28?μM) with DHA (GPR40 ligand) as a positive control (EC50=3.85?μM) in hGPR40-CHO cells.
Vincamine?is a monoterpenoid indole alkaloid extracted from the?Madagascar periwinkle. Vincamine?is a peripheral?vasodilator?and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine?is a?GPR40?agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS).?Vincamine?improves glucose homeostasis?in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.
体内研究：
Vincamine (intraperitoneal injection; 15 and 30?mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion?in vivo.Animal Model:Male and female db/db mice (BKS.Cg-Dock7m+/+Leprdb/J) and HFD/STZ-induced type 2 diabetic model mice
Dosage:15 and 30?mg/kg/day
Administration:Intraperitoneal injection; 15 and 30?mg/kg/day; 6 weeks
Result:Enhanced glucose tolerance in HFD/STZ and?db/db male mice.
体外研究：
Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi?cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells.Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, ?after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner.Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer.Vincamine could activate GPR40 (EC50=6.28?μM) with DHA (GPR40 ligand) as a positive control (EC50=3.85?μM) in hGPR40-CHO cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备